Expertise in
6
conditions

Dr. Gail L. Torkildsen

Ophthalmology
Andover Eye Associates Inc.
138 Haverhill St Ste 104, 
Andover, MA 
Expertise in
6
conditions
Andover Eye Associates Inc.
138 Haverhill St Ste 104, 
Andover, MA 

Overview

Gail Torkildsen is an Ophthalmologist practicing medicine in Andover, Massachusetts.

Dr. Torkildsen is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Giant Papillary Conjunctivitis, Vernal Keratoconjunctivitis, Allergic Conjunctivitis, and Chemosis.

She is actively involved in clinical research, co-authoring 22 peer reviewed articles and participating in 7 clinical trials.

Specialties

Ophthalmology

Licenses

Ophthalmology in MA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Tufts
  • HMO

Locations

Andover Eye Associates Inc.
138 Haverhill St Ste 104, Andover, MA 01810

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine /Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine /Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Enrollment Status: Completed
Publish Date: September 05, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease (COMET-1)
A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease (COMET-1)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: AR15512, Vehicle
Study Phase: Phase 2
Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Randomized, Controlled, Multicenter, Double-Masked, Parallel, Phase 2b/3 Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drug: Lotilaner Ophthalmic Solution
Study Phase: Phase 2/Phase 3
A Single-Center, Randomized, Double Masked, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of iNexin™ Eye Drops Compared to Vehicle in Subjects With Dry Eye Disease
A Single-Center, Randomized, Double Masked, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of iNexin™ Eye Drops Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: March 04, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Subjects With Dry Eye Using the Controlled Adverse Environment (CAE) Model
A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution in Subjects With Dry Eye Using the Controlled Adverse Environment (CAE) Model
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model
A Phase 2, Single Center, Randomized, Double-Masked and Placebo Controlled Study Evaluating the Efficacy of Three Different Concentrations (0.1, 1.0, 5.0%) of SAR 1118 Ophthalmic Solution in a Modified Conjunctival Allergen Challenge (CAC) Model
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
View 5 Less Clinical Trials

22 Total Publications

Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Published: September 07, 2023
Similar Doctors
Expertise in
27
conditions
Dr. Jeffrey S. Heier
Ophthalmology
Expertise in
27
conditions
Dr. Jeffrey S. Heier
Ophthalmology
Referral may be required

Ophthalmic Consultants Of Boston Inc

50 Staniford St Ste 600, 
Boston, MA 
 (20.3 miles away)
617-367-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jeffrey Heier is an Ophthalmologist practicing medicine in Boston, Massachusetts. Dr. Heier is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Retinal Vein Occlusion, and Vitrectomy. Dr. Heier is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Massachusetts Eye And Ear

243 Charles St, 
Boston, MA 
 (20.3 miles away)
617-573-6874
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Demetrios Vavvas is an Ophthalmologist practicing medicine in Boston, Massachusetts. Dr. Vavvas is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Retinal Detachment, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal. Dr. Vavvas is currently accepting new patients.

Expertise in
25
conditions
Dr. John B. Miller
Ophthalmology
Expertise in
25
conditions
Dr. John B. Miller
Ophthalmology
Referral may be required
Before you request

Mass Eye And Ear, Ophthalmology

243 Charles Street, 
Boston, MA 
 (20.3 miles away)
617-573-3750
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Miller is an Ophthalmologist practicing medicine in Boston, Massachusetts. He has been practicing medicine for over 17 years. Dr. Miller is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Vein Occlusion, Retinal Detachment, and Vitrectomy. Dr. Miller is board certified in Ophthalmology. Dr. Miller is currently accepting new patients.

Frequently Asked Questions about Dr. Gail L. Torkildsen

How do I make an appointment with Dr. Gail L. Torkildsen?

You can book an appointment with Dr. Gail L. Torkildsen by calling their office at 978-475-0705. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gail L. Torkildsen a top-rated expert for Giant Papillary Conjunctivitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gail L. Torkildsen is classified as an Elite expert for Giant Papillary Conjunctivitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gail L. Torkildsen specialize in?

While Dr. Gail L. Torkildsen is a Ophthalmology, they have specific expertise in Giant Papillary Conjunctivitis, Vernal Keratoconjunctivitis, and Allergic Conjunctivitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Ophthalmology.

Does Dr. Gail L. Torkildsen participate in research or clinical trials?

Yes. Dr. Gail L. Torkildsen has published 22 articles and abstracts on conditions like Giant Papillary Conjunctivitis. You can view a list of Dr. Gail L. Torkildsen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gail L. Torkildsen accept my insurance?

Dr. Gail L. Torkildsen accepts most major insurance plans, including Anthem BCBS and Medicare. We recommend calling the office directly at 978-475-0705 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Torkildsen's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile